Literature DB >> 33926085

The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD.

Emmanuel D Dixon1, Alexander D Nardo1, Thierry Claudel1, Michael Trauner1.   

Abstract

Obesity and type 2 diabetes mellitus (T2DM) are metabolic disorders characterized by metabolic inflexibility with multiple pathological organ manifestations, including non-alcoholic fatty liver disease (NAFLD). Nuclear receptors are ligand-dependent transcription factors with a multifaceted role in controlling many metabolic activities, such as regulation of genes involved in lipid and glucose metabolism and modulation of inflammatory genes. The activity of nuclear receptors is key in maintaining metabolic flexibility. Their activity depends on the availability of endogenous ligands, like fatty acids or oxysterols, and their derivatives produced by the catabolic action of metabolic lipases, most of which are under the control of nuclear receptors. For example, adipose triglyceride lipase (ATGL) is activated by peroxisome proliferator-activated receptor γ (PPARγ) and conversely releases fatty acids as ligands for PPARα, therefore, demonstrating the interdependency of nuclear receptors and lipases. The diverse biological functions and importance of nuclear receptors in metabolic syndrome and NAFLD has led to substantial effort to target them therapeutically. This review summarizes recent findings on the roles of lipases and selected nuclear receptors, PPARs, and liver X receptor (LXR) in obesity, diabetes, and NAFLD.

Entities:  

Keywords:  NAFLD; diabetes; metabolic lipase; nuclear receptor; obesity

Year:  2021        PMID: 33926085     DOI: 10.3390/genes12050645

Source DB:  PubMed          Journal:  Genes (Basel)        ISSN: 2073-4425            Impact factor:   4.096


  219 in total

1.  Suppression of PPARγ through MKRN1-mediated ubiquitination and degradation prevents adipocyte differentiation.

Authors:  J-H Kim; K W Park; E-W Lee; W-S Jang; J Seo; S Shin; K-A Hwang; J Song
Journal:  Cell Death Differ       Date:  2013-12-13       Impact factor: 15.828

2.  Isoproterenol, TNFalpha, and insulin downregulate adipose triglyceride lipase in 3T3-L1 adipocytes.

Authors:  Susan Kralisch; Johannes Klein; Ulrike Lossner; Matthias Bluher; Ralf Paschke; Michael Stumvoll; Mathias Fasshauer
Journal:  Mol Cell Endocrinol       Date:  2005-08-30       Impact factor: 4.102

3.  Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.

Authors:  Giovanni Musso; Maurizio Cassader; Elena Paschetta; Roberto Gambino
Journal:  JAMA Intern Med       Date:  2017-05-01       Impact factor: 21.873

4.  Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element.

Authors:  P Gervois; S Chopin-Delannoy; A Fadel; G Dubois; V Kosykh; J C Fruchart; J Najïb; V Laudet; B Staels
Journal:  Mol Endocrinol       Date:  1999-03

5.  Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA.

Authors:  Vikas Chandra; Pengxiang Huang; Yoshitomo Hamuro; Srilatha Raghuram; Yongjun Wang; Thomas P Burris; Fraydoon Rastinejad
Journal:  Nature       Date:  2008-11-20       Impact factor: 49.962

6.  Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.

Authors:  Vlad Ratziu; Philippe Giral; Sophie Jacqueminet; Fréderic Charlotte; Agnès Hartemann-Heurtier; Lawrence Serfaty; Philippe Podevin; Jean-Marc Lacorte; Carole Bernhardt; Eric Bruckert; André Grimaldi; Thierry Poynard
Journal:  Gastroenterology       Date:  2008-04-08       Impact factor: 22.682

7.  Loss of PPAR gamma in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into white adipose tissue.

Authors:  Amir J Guri; Raquel Hontecillas; Gerardo Ferrer; Oriol Casagran; Umesh Wankhade; Alexis M Noble; Decio L Eizirik; Fernanda Ortis; Miriam Cnop; Dongmin Liu; Hongwei Si; Josep Bassaganya-Riera
Journal:  J Nutr Biochem       Date:  2007-07-06       Impact factor: 6.048

8.  Liver X receptor α mediates hepatic triglyceride accumulation through upregulation of G0/G1 Switch Gene 2 expression.

Authors:  Bradlee L Heckmann; Xiaodong Zhang; Alicia M Saarinen; Gabriele Schoiswohl; Erin E Kershaw; Rudolf Zechner; Jun Liu
Journal:  JCI Insight       Date:  2017-02-23

9.  Reciprocal regulation of hepatic and adipose lipogenesis by liver X receptors in obesity and insulin resistance.

Authors:  Simon W Beaven; Aleksey Matveyenko; Kevin Wroblewski; Lily Chao; Damien Wilpitz; Tu Wen Hsu; Jacob Lentz; Brian Drew; Andrea L Hevener; Peter Tontonoz
Journal:  Cell Metab       Date:  2013-07-02       Impact factor: 27.287

10.  LXRs link metabolism to inflammation through Abca1-dependent regulation of membrane composition and TLR signaling.

Authors:  Ayaka Ito; Cynthia Hong; Xin Rong; Xuewei Zhu; Elizabeth J Tarling; Per Niklas Hedde; Enrico Gratton; John Parks; Peter Tontonoz
Journal:  Elife       Date:  2015-07-14       Impact factor: 8.140

View more
  8 in total

1.  Developmental Programming: Prenatal Testosterone Excess on Liver and Muscle Coding and Noncoding RNA in Female Sheep.

Authors:  Nadia Saadat; Muraly Puttabyatappa; Venkateswaran R Elangovan; John Dou; Joseph N Ciarelli; Robert C Thompson; Kelly M Bakulski; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2022-01-01       Impact factor: 4.736

2.  Nonalcoholic Steatohepatitis, Peroxisome Proliferator-Activated Receptors and Our Good Glitazar: Proof of the Pudding is in the Eating.

Authors:  Anil C Anand; Subrata K Acharya
Journal:  J Clin Exp Hepatol       Date:  2022-01-25

Review 3.  The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD.

Authors:  Ting Hong; Yiyan Chen; Xiaoying Li; Yan Lu
Journal:  Oxid Med Cell Longev       Date:  2021-10-27       Impact factor: 6.543

Review 4.  Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease.

Authors:  Stanislav Kotlyarov; Aleksei Bulgakov
Journal:  Cells       Date:  2021-11-01       Impact factor: 6.600

Review 5.  The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases.

Authors:  Jianjun Gao; Zhaoyan Gu
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

Review 6.  Mongolian medicine in treating type 2 diabetes mellitus combined with nonalcoholic fatty liver disease via FXR/LXR-mediated P2X7R/NLRP3/NF-κB pathway activation.

Authors:  Shuyin Bao; Xiuzhi Wang; Qianqian Ma; Chengxi Wei; Jixing Nan; Wuliji Ao
Journal:  Chin Herb Med       Date:  2022-07-19

7.  Lentinan Protects against Nonalcoholic Fatty Liver Disease by Reducing Oxidative Stress and Apoptosis via the PPARα Pathway.

Authors:  Tingyi Du; Qin Fang; Zhihao Zhang; Chuanmeng Zhu; Renfan Xu; Guangzhi Chen; Yan Wang
Journal:  Metabolites       Date:  2022-01-10

Review 8.  Physiological Role of Bile Acids Modified by the Gut Microbiome.

Authors:  Yoshimitsu Kiriyama; Hiromi Nochi
Journal:  Microorganisms       Date:  2021-12-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.